



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

**Summary for ARTG Entry:** 296390 TRIM 1+1

**ARTG entry for** Medicine Listed  
**Sponsor** Caredin  
**Postal Address** D2 2A Westall Road, Clayton, VIC, 3168  
 Australia  
**ARTG Start Date** 16/11/2017  
**Product category** Medicine  
**Status** Active  
**Approval area** Listed Medicines

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1. TRIM 1+1**

Product Type	Composite Pack	Effective date	16/11/2017
--------------	----------------	----------------	------------

**Permitted Indications**

No Permitted Indications included on Record

**Indication Requirements**

No Indication Requirements included on Record

**Standard Indications**

Aids, assists or helps in the maintenance or improvement of general well-being.

**Specific Indications**

Poliglusam derived from *Aspergillus niger* (Chitosan) binds fat, reduces fat absorption and promotes fat loss maintaining normal levels in healthy individuals. May assist in healthy body weight maintenance when taken as directed, in conjunction with a calorie-controlled diet and appropriate exercise program. *Camellia sinensis* (Green tea extract) is rich in bioactive flavonoids such as epigallocatechin gallate (EGCG) that have significant antioxidant activity. Green tea extract helps to promote thermogenesis/fat burning when combined with a calorie controlled diet and healthy exercise program. Green tea extract supports the health and function of cardiovascular system. Contains chromium which is the main component of glucose tolerance factor in normal healthy individuals. Chromium is an essential nutrient required for carbohydrate, lipid and protein metabolism. Magnolia assists to regulate physiological stress response thereby controlling stress-induced over-eating. Magnolia also helps to relieve mild anxiety induced disturbed sleep. *Phaseolus vulgaris* reduces digestion of dietary starches through inhibition of the digestive enzyme, alpha amylase. It helps in balancing caloric intake from high starch carbohydrate meals and supports in maintaining healthy body weight. Contains psyllium husk which provides dietary fibre and promotes healthy bowel movement assisting in weight loss. Viscous and gel forming psyllium aids in weight loss through promoting satiety and decreasing hunger. Contains psyllium which is traditionally used in Western herbal medicine as a demulcent for the symptomatic relief of mild gastrointestinal discomfort. Contains ingredients that help in reducing constipation.

**Warnings**

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] [must be clear and legible].

Drink plenty of water (or words to that effect).

Poliglusam should be taken at least one hour after any other medication as it may reduce the effect of other medication' (or words to that effect).



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

'Contains gluten (or words to that effect)'

If symptoms persist consult your healthcare practitioner (or words to that effect).

Adults only (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1. CARB Remover**

**Dosage Form**

Powder

**Route of Administration**

Oral

**Visual Identification**

**Active Ingredients**

**Avena sativa**

**113.77 mg/g**

**Cistanche deserticola**

**56.88 mg/g**

Equivalent: Cistanche deserticola (Dry)

1.1376 g/g

**Phaseolus vulgaris**

**227.53 mg/g**

Equivalent: Phaseolus vulgaris (Dry)

2.275 g/g

**Psyllium Husk Powder**

**455.06 mg/g**

**2. FAT Eraser**

**Dosage Form**

Tablet, uncoated

**Route of Administration**

Oral

**Visual Identification**

**Active Ingredients**

**Camellia sinensis**

**125 mg**

Equivalent: Camellia sinensis (Dry)

3.75 g

**chromium picolinate**

**.0503 mg/g**

**Magnolia officinalis**

**50 mg**

Equivalent: Magnolia officinalis (Dry)

1000 mg

**poliglusam derived from aspergillus niger**

**425 mg**

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary